Profile data is unavailable for this security.
About the company
Medincell SA is a France-based manufacturer of biological products and pharmaceutical preparations. The Company is focused on the development of therapeutic solutions with worldwide access. The Company works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.
- Revenue in EUR (TTM)10.85m
- Net income in EUR-26.42m
- Incorporated2002
- Employees138.00
- LocationMedincell SA3 rue des Freres LumiereJACOU 34830FranceFRA
- Phone+33 467021367
- Websitehttps://www.medincell.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sensorion SA | 0.00 | -22.06m | 225.19m | 50.00 | -- | 4.22 | -- | -- | -0.2063 | -0.2063 | 0.00 | 0.1779 | 0.00 | -- | -- | -- | -51.64 | -35.12 | -71.66 | -46.97 | -- | -- | -- | -- | -- | -- | 0.0794 | -- | -- | -- | 4.94 | -- | 126.45 | -- |
| Nanobiotix SA | 30.06m | -39.70m | 237.08m | 102.00 | -- | -- | -- | 7.89 | -1.10 | -1.10 | 0.814 | -0.0391 | 0.3912 | -- | 19.59 | 294,686.30 | -51.67 | -54.11 | -120.56 | -80.68 | -- | -- | -132.08 | -756.15 | -- | -1.98 | 1.04 | -- | -- | 203.88 | 30.40 | -- | -7.81 | -- |
| Genfit SA | 38.18m | -28.89m | 245.07m | 159.00 | -- | 3.60 | -- | 6.42 | -0.5814 | -0.5814 | 0.7681 | 1.36 | 0.1961 | 542.00 | 3.52 | 240,100.60 | -14.84 | -12.57 | -18.55 | -15.30 | 94.32 | 94.96 | -75.69 | -76.23 | 2.94 | -7.78 | 0.5080 | -- | 43.70 | 38.49 | -21.82 | -- | -3.27 | -- |
| Euroapi SA | 1.02bn | -189.70m | 293.08m | 3.67k | -- | 0.3134 | -- | 0.2876 | -2.01 | -2.01 | 10.73 | 9.78 | 0.6086 | 1.38 | 4.24 | 277,705.10 | -11.34 | -- | -15.93 | -- | 16.15 | -- | -18.63 | -- | 0.6573 | -- | 0.1955 | -- | 3.87 | -- | -1,164.67 | -- | -- | -- |
| Carbios SA | 24.00k | -27.22m | 379.03m | 134.00 | -- | 1.62 | -- | 15,792.78 | -2.03 | -2.03 | 0.0017 | 13.92 | 0.0001 | -- | 0.7619 | 179.10 | -11.20 | -9.92 | -12.13 | -10.77 | -4,783.33 | -- | -113,433.30 | -3,365.22 | 9.43 | -23.97 | 0.1517 | -- | -65.71 | -53.32 | 1.86 | -- | 141.01 | -- |
| Medincell SA | 10.85m | -26.42m | 429.39m | 138.00 | -- | -- | -- | 39.59 | -1.02 | -1.02 | 0.4086 | -0.8965 | 0.2605 | -- | 6.81 | -- | -63.46 | -- | -115.15 | -- | 60.43 | -- | -243.58 | -366.40 | -- | -4.29 | 1.69 | -- | -8.67 | 44.33 | 21.78 | -- | -- | -- |
| Guerbet SA | 785.69m | 23.87m | 480.99m | 2.92k | 21.15 | 1.27 | 5.77 | 0.6122 | 1.80 | 1.80 | 62.15 | 29.97 | 0.7997 | 0.5983 | 5.80 | 269,071.90 | 2.26 | 1.40 | 2.96 | 1.86 | 78.01 | 76.02 | 2.82 | 1.82 | 1.21 | 5.62 | 0.5035 | 57.82 | 4.30 | -0.0993 | 158.05 | -12.61 | 5.23 | -10.07 |
| Valneva SE | 152.96m | -24.39m | 525.07m | 684.00 | -- | 2.77 | 10.27 | 3.43 | -0.1943 | -0.1943 | 1.10 | 1.36 | 0.2799 | 2.34 | 5.63 | 223,622.80 | -4.46 | -15.39 | -6.84 | -25.06 | 32.95 | 35.94 | -15.95 | -34.95 | 2.22 | -2.69 | 0.528 | -- | -57.46 | 6.34 | 29.21 | -- | 35.18 | -- |
| Boiron SA | 493.25m | 35.83m | 621.11m | 2.81k | 17.16 | 1.56 | 11.22 | 1.26 | 2.06 | 2.06 | 28.41 | 22.67 | 0.715 | 1.40 | 5.26 | 175,533.10 | 4.92 | 4.59 | 6.16 | 5.76 | 72.60 | 74.02 | 6.88 | 6.80 | 1.50 | -- | 0.0338 | 53.86 | -7.67 | -3.98 | -19.80 | -9.01 | -17.68 | -1.42 |
| Holder | Shares | % Held |
|---|---|---|
| Mirova SA (Investment Management)as of 30 Jun 2023 | 2.27m | 7.81% |
| Syquant Capital SASas of 31 Dec 2023 | 728.73k | 2.51% |
| Polar Capital LLPas of 30 Apr 2024 | 388.41k | 1.34% |
| BFT Investment Managers SAas of 30 Apr 2024 | 304.61k | 1.05% |
| Saint Olive Gestion SNCas of 29 Dec 2023 | 245.00k | 0.84% |
| Mandarine Gestion SAas of 29 Feb 2024 | 155.50k | 0.54% |
| Amundi Asset Management SA (Investment Management)as of 30 Apr 2024 | 143.49k | 0.49% |
| SG 29 Haussmann SASUas of 05 Jun 2024 | 139.00k | 0.48% |
| Soci�t� G�n�rale Gestion SAas of 30 Apr 2024 | 119.97k | 0.41% |
| Tocqueville Finance SAas of 31 Jan 2024 | 117.91k | 0.41% |
